Browsing by Author "Vikas Sharma"

Now showing 1 - 4 of 4

Development of intron length polymorphic (ILP) markers in onion (Allium cepa L.), and their cross-species transferability in garlic (A. sativum L.) and wild relatives
(Springer Netherlands, 2019) Kuldip Jayaswall; Himanshu Sharma; Abhishek Bhandawat; Ram Sagar; Vinod Kumar Yadav; Vikas Sharma; Vijay Mahajan; Joy Roy; Major Singh
Onion (Allium cepa L.) is a popular spice and a plant of high medicinal value. Conventional breeding and genetic improvement efforts were largely limited due to self-incompatibility and heterozygosity. Recently, marker assisted breeding has significantly reduced time and labour in developing elite varieties. But very limited polymorphic and cross-transferable markers are available in onion. There is an urgent need to develop polymorphic markers in Allium to expedite and introgress desirable traits from wild relatives (which are rich bioresource of various biotic and abiotic resistance genes) to A. cepa. Considering limited availability of reliable molecular markers in Allium and wild relatives, in current study, 20,204 ESTs (3750 contigs and 8364 singletons), of A. cepa were successfully utilized for identification of over 2689 intron length polymorphic (ILP) markers. A set of 30 markers was tested for polymorphism in onion and cross-transferability in garlic and related wild species. Among these, eighteen markers amplified at least one of the accessions of A. cepa. Transferability of these ILP markers was ranged from 21.7 to 95.7% in Allium spp. Low level of polymorphism in A. cepa compared to wild Allium species is reported. Based on the Jaccard dissimilarity matrix, a neighbour-joining tree was constructed, which clustered all the 23 varieties/accessions under three groups. All the varieties of A. cepa were clearly clustered separately under group I. However, there was intermixing of varieties/accessions of A. sativum L. and wild relatives, which may possibly be due to less number of markers validated for cross-transferability. In future, larger set of markers will be used to resolve the genetic variations among wild varieties and A. sativum These 18 polymorphic ILP markers could be utilised for diversity characterization of Allium spp., varietal identification, mapping of genes and introgression of desirable traits from wild relatives. © 2019, Springer Nature B.V.
Gender Justice and Legal Frameworks in India: A Comprehensive Research Study on Women’s Rights, Regional Disparities, and the Role of Law in Social and Spatial Development
(Green Publication, 2025) Shruti Das; Vikas Sharma; Priti Rupa Saikia; Srutakirti Panda; Divya S. Khurana; Mukesh Kumar Malviya
Gender justice in India continues to be shaped by the intersection of legal frameworks, institutional accessibility, and spatial development. Despite progressive constitutional guarantees and legislative reforms, disparities in women’s empowerment persist due to uneven socio-economic conditions and regional inequalities. This study adopts an integrated analytical framework combining quantitative, qualitative, and geospatial methods to examine patterns of gender justice across Indian states. Multi-dimensional datasets from legal, social, developmental, and spatial domains were analysed to assess institutional effectiveness, policy implementation, and access to justice. The findings reveal significant regional disparities, with states such as Kerala, Tamil Nadu, and Himachal Pradesh performing better in literacy, workforce participation, and legal infrastructure, while states like Bihar, Uttar Pradesh, and Rajasthan continue to exhibit limited institutional outreach and high vulnerability, forming “justice deserts.” Spatial visualisations highlight clusters of disadvantage, particularly in rural and underserved areas, while statistical correlations demonstrate that lower Gender Inequality Index (GII) values align with higher Human Development Index (HDI) scores. The study concludes that achieving equitable gender justice requires region-specific legal interventions, targeted institutional strengthening, and the integration of spatial planning strategies to promote sustainable social and regional development. © 2025, Green Publication. All rights reserved.
Role of bile bacteria in gallbladder carcinoma
(2007) Vikas Sharma; Vikrant Singh Chauhan; Gopal Nath; Anil Kumar; Vijay Kumar Shukla
Background/Aims: Long standing calculus disease has been observed to be a risk factor for gallbladder carcinoma. However it is possible that calculi may be incriminated by some means other than just chronic irritation. Calculi may induce an element of stasis, promoting chronic infection leading to increased turnover of primary bile acids to secondary bile acids, which are known tumor promoters and initiators. This study aimed to find the prevalence of biliary microflora in gallbladder carcinoma and association of gallbladder carcinoma with chronic bacterial infection and bile acid profile. Methodology: Bile culture was done in 390 patients divided into 3 groups - gallbladder carcinoma 65 (17%), cholelithiasis 125 (32%) and control group 200 (51%). Serum samples were analyzed for presence of Vi antibody for chronic typhoid carrier state and bile acid analysis was done in 10 patients in each group. Results: 116 (30%) patients had culture positive bile. Significantly higher number of patients with gallbladder carcinoma 40 (65%) had culture positive bile as compared to cholelithiasis 52 (42%) and control 24 (12%). Vi Antibodies suggestive of chronic typhoid carrier state were found to be significantly higher in the gallbladder carcinoma group 20 (31%) as compared to controls 22 (11%) (OR 3.596, p< 0.05) however, the difference was statistically insignificant in the cholelithiasis group 12 (11%) (OR 0.859, p>0.05). There was a 6.84 times higher risk of developing gallbladder carcinoma in culture positive cholelithiasis patients and 5.14 times if both Vi antibody and cultures were positive. Bile analysis showed primary bile acids cholic acid and chenodeoxycholic acid to be lower while secondary bile acids deoxycholic acid and lithocholic acid to be more in the gallbladder carcinoma group (7.268mg/mL, 9.183mg/mL, 14.468mg/mL, 3.312mg/mL respectively) than cholelithiasis (17.50mg/mL, 13.80mg/mL, 6.07mg/mL, 2.05mg/mL) and control group (19.85mg/mL, 16.53mg/mL, 2.71mg/mL, 1.128mg/mL respectively). The difference was statistically significant. Conclusions: Chronic bacterial infection of bile leading to production of carcinogenic precursors might be one of the etiological factors in the pathogenesis of gallbladder carcinoma and hence a target for its prevention. © H.G.E. Update Medical Publishing S.A.
Therapeutic potential of p53 reactivation in prostate cancer: Strategies and opportunities
(Elsevier B.V., 2022) Sangeeta Kumari; Vikas Sharma; Rahul Tiwari; Jay Prakash Maurya; Bharat Bhusan Subudhi; Dhirodatta Senapati
Metastatic prostate cancer (mCaP) remains one of the leading causes of cancer-related death in men worldwide. Androgen receptor (AR) drives the progression of most of the mCaP, and hence the androgen deprivation therapy (ADT) is the first-line treatment of choice for mCaP. Although the responses of ADT and next-generation AR inhibitors initially improve the disease burden, the responses of this combinatorial drug therapy varied widely due to molecular alteration in mCaP patients. In addition to the altered AR signaling, loss of potent tumor-suppressor protein p53 exhibits poor outcomes. p53 influences cell plasticity and is frequently lost in more aggressive prostate cancer (CaP) with neuroendocrine differentiation. Loss of p53 antagonizes the effect of AR inhibitors and enhances the proliferation rate of CaP cells. Considering the important role of p53 inactivation in cancer development, restoration of wild-type p53 function by p53-reactivating compounds developed with different approaches, seems to be an attractive therapeutic strategy for prostate cancer therapy. In this review, we discuss the therapeutic potential of these compounds with a particular focus on the pharmacological rescue of p53 in mCaP. In addition, we also highlight the challenges and new opportunities of p53-targeted therapy for the future. © 2022